These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32629401)

  • 1. Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?
    Saposnik G; Sotoca J; Sempere ÁP; Candeliere-Merlicco A; Díaz-Abós P; Tobler PN; Terzaghi M; Maurino J
    Mult Scler Relat Disord; 2020 Oct; 45():102354. PubMed ID: 32629401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.
    Saposnik G; Andhavarapu S; Sainz de la Maza S; Castillo-Triviño T; Borges M; Barón BP; Sotoca J; Alonso A; Caminero AB; Borrega L; Sánchez-Menoyo JL; Barrero-Hernández FJ; Calles C; Brieva L; Blasco MR; García-Soto JD; Del Campo-Amigo M; Navarro-Cantó L; Agüera E; Garcés M; Carmona O; Gabaldón-Torres L; Forero L; Hervás M; García-Arcelay E; Terzaghi M; Gómez-Ballesteros R; Maurino J
    Mult Scler Relat Disord; 2022 Dec; 68():104138. PubMed ID: 36029707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis.
    Castillo-Triviño T; Gómez-Ballesteros R; Borges M; Martín-Martínez J; Sotoca J; Alonso A; Caminero AB; Borrega L; Sánchez-Menoyo JL; Barrero-Hernández FJ; Calles C; Brieva L; Blasco-Quílez MR; García-Soto JD; Del Campo-Amigo M; Navarro-Cantó L; Agüera E; Garcés-Redondo M; Carmona O; Gabaldón-Torres L; Forero L; Hervás M; Mauriño J; Sainz de la Maza S
    Mult Scler Relat Disord; 2022 Aug; 64():103969. PubMed ID: 35728432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.
    Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G
    Patient; 2021 Mar; 14(2):241-248. PubMed ID: 32975737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.
    Sabin J; Salas E; Martín-Martínez J; Candeliere-Merlicco A; Barrero Hernández FJ; Alonso Torres AM; Sánchez-Menoyo JL; Borrega L; Rodríguez-Rodríguez M; Gómez-Gutiérrez M; Eichau S; Hernández-Pérez MÁ; Calles C; Fernandez-Diaz E; Carmona O; Orviz A; López-Real A; López-Muñoz P; Mendoza Rodríguez A; Aguera-Morales E; Maurino J
    Patient Prefer Adherence; 2024; 18():1163-1171. PubMed ID: 38863945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain.
    Almusalam N; Oh J; Terzaghi M; Maurino J; Bakdache F; Montoya A; Caceres F; Saposnik G
    JAMA Netw Open; 2019 Jul; 2(7):e197093. PubMed ID: 31314113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang LN; Zhan S; Xia Y
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
    van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J
    J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
    Siddiqui MK; Singh B; Attri S; Veraart C; Harty G; Wong SL
    Curr Med Res Opin; 2020 May; 36(5):809-826. PubMed ID: 32129684
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.